Dechert Advises ArchiMed in the recapitalisation of Polyplus

Dechert LLP advised ArchiMed, a European investment firm specialized in the Healthcare industries, in the partial sale of Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy, to Warburg Pincus, a global private equity firm focused on growth investing.

Following an auction process led by Jefferies, Dechert also assisted ArchiMed on its reinvestment, alongside Warburg Pincus, in the Polyplus group, which ArchiMed had controlled since 2016. As a result of the transaction, ArchiMed and Warburg Pincus will be equal shareholders in this secondary buyout, with the same voting rights. Management will remain significant minority shareholders.

A multi-disciplinary team from Dechert’s Paris office, in coordination with the New York and Washington, D.C. offices and led by Paris office managing partner Alain Decombe, advised ArchiMed on the following:

• M&A aspects:
  • On the sale: Isabelle Marguet, national partner, assisted by Anne-Sophie Gallot;
  • On reinvestment: Anne-Charlotte Rivière, partner, assisted by Xavier Leroux and Johann Gandilhon;
• Tax structuring aspects: Sabina Comis, partner, assisted by Etienne Bimbeau;
• Competition aspects: Mélanie Thill-Tayara, partner, assisted by Marion Provost and Delphine Strohl;
• Financing aspects: Privat Vigand, partner, assisted by Guénaelle Taroni and Pauline Keller;
• Pharmaceutical regulatory aspects and foreign investment in France: Sophie Pelé, national partner, assisted by Jessica Garestier and Sophie Mitouard; and
• Intellectual property aspects: Marie Fillon, national partner, assisted by Louis de Chezelles.

Translate page into French.

About Dechert

Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.